REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | |
| Balance as of December 31, 2021 (as previously reported) | — | $— | 282,039 | $282 | $14,417,547 | $(14,517,299) | $(99,470) |
| Retrospective application of reverse recapitalization | — | — | (272,644) | (218) | 218 | — | — |
| Reverse stock split fractional stock round up | — | — | 54,626 | — | — | — | — |
| Balance at December 31, 2021 | — | $— | 64,021 | $64 | $14,417,765 | $(14,517,299) | $(99,470) |
| Issuance of common stock in connection with the Business Combination, net | — | — | 3,274 | 3 | 6,864,324 | — | 6,864,327 |
| Issuance of common stock for fees in connection with the Business Combination | — | — | 286 | 1 | 299 | — | 300 |
| Proceeds from the PIPE Investment, net | — | — | 1,232 | 1 | 7,262,218 | — | 7,262,219 |
| Rollover Warrant exercise | — | — | 2 | — | 5,074 | — | 5,074 |
| Repurchase for the Forward Share Purchase Agreement exercise | — | — | (715) | (1) | (7,652,324) | — | (7,652,325) |
| Class A Pre-Funded Warrants exercise | — | — | 1,232 | 1 | 12 | — | 13 |
| Proceeds from the July 2022 Public Offering, net | — | — | 7,937 | 7 | 4,451,041 | — | 4,451,048 |
| RSU awards issued | — | — | 106 | 1 | (1) | — | — |
| Issuance of common stock for Accrued Expenses in connection with the Business Combination | — | — | — | — | 749,700 | — | 749,700 |
| Issuance of Series A Preferred Stock | 1 | — | — | — | — | — | — |
| Stock-based compensation expense | — | — | — | — | 301,116 | — | 301,116 |
| Net loss | — | — | — | — | — | (10,829,549) | (10,829,549) |
| Balance at December 31, 2022 | — | $— | 77,375 | $77 | $26,399,224 | $(25,346,848) | $1,052,453 |
| Balance as of December 31, 2022 (as previously reported) | 1 | $— | 682,882 | $683 | $26,398,618 | $(25,346,848) | $1,052,453 |
| Retrospective application of reverse recapitalization | — | — | (660,133) | (606) | 606 | — | — |
| Reverse stock split fractional stock round up | — | — | 54,626 | — | — | — | — |
| Balance at December 31, 2022 | 1 | $— | 77,375 | $77 | $26,399,224 | $(25,346,848) | $1,052,453 |
| Redemption of Series A Preferred Stock | (1) | — | — | — | — | — | — |
| Issuance of common stock from the February 2023 Public Offering | — | — | 96,287 | 96 | 33,378 | — | 33,474 |
| Class C Pre-Funded Warrants exercise | — | — | 11,214 | 11 | 23 | — | 34 |
| Alternative cashless exercise of Class C Common Stock Warrants | — | — | 79,521 | 80 | 5,526,207 | — | 5,526,287 |
| RSU awards issued | — | — | 140 | 1 | (1) | — | — |
| Stock-based compensation expense | — | — | — | — | 155,721 | — | 155,721 |
| Net loss | — | — | — | — | — | (120,254) | (120,254) |
| Balance as of December 31, 2023 | — | $— | 264,537 | $265 | $32,114,552 | $(25,467,102) | $6,647,715 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.